Shots:
- The US FDA has received an NDA for ecopipam, a selective dopamine D1 receptor antagonist, for the treatment of pediatric Tourette syndrome
- NDA was supported by the P-III trial data showing that ecopipam significantly delayed time to relapse vs PBO in pediatric Tourette syndrome pts who responded to treatment during the open-label treatment period; data were published in the JAMA Neurology
- Ecopipam is designed to block dopamine signaling at the D1 receptor, which received Orphan Drug & Fast Track designations from the FDA for the treatment of pediatric pts with Tourette syndrome
Ref: Teva | Image: Teva | Press Release
Related News: Teva Launches Ahzantive (Biosimilar, Eylea) Across Key EU Markets
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
